| General Information of Drug Metabolite (DM) (ID: DM005713) |
| DM Name |
Keto CC-223
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Unclear - Unclear |
CC-223
|
[1] |
|
Cytochrome P450 3A5 (CYP3A5)
|
DME0012
|
| Unclear - Unclear |
CC-223
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| CC-223 |
DR1819
|
Phase 1/2 |
Lung cancer |
|
|
| References |
| 1 |
Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. Xenobiotica. 2019 Jan;49(1):54-70.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
